Reading CTSO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTSO free→Reading CTSO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTSO free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, with CTSO trading below typical compared to sector peers. Peer multiples imply a price about 78% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.52. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.43 CTSO trades at 1× p/s, below its 3× p/s peer median. Our $2.43 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 78% below a flat-multiple fair value, below our forecast of about 5%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.85x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.05 → $-0.04 (+13.4% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 0% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$255.
How much price usually moves either way.
On a bad day, this stock has moved -$778.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,991.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show if CytoSorbents can improve its financial performance. Investors will look for signs of recovery.
Confirms one read:The earnings report shows revenue growth or smaller losses than last quarter.
Confirms the other:The earnings report shows more losses or less revenue than last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CTSO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 13, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.*
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CTSO CytoSorbents Corp | Below typical Show detailsSector percentile: 14 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve operating cash flow breakeven in the second half of 2026.
Management is focused on improving gross margins as part of their operational strategy.
Why it matters: If healthcare sector growth speeds up, it could help CytoSorbents improve its performance. It shows the market is strengthening.
Confirms:Healthcare sector revenue growth speeds up to 10% or more.
Disproves:Healthcare sector revenue growth continues to slow or stays below 10%.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 1, 2026, CytoSorbents Corporation, a Delaware corporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00…
Results of Operations and Financial Condition. On March 25, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 2, 2025, CytoSorbents Corporation (the “Company”) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The written…